The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 401–500 of 1,000
Kazianka, L., Drucker, C., Skrabs, C., Thomas, W., Melchardt, T., Struve, S., Bergmann, M. M., Staber, P. B., Porpaczy, E. A., Einberger, C., et al. (2016) · Leukemia · doi:10.1038/leu.2016.316 · Cited by 43
Targeting of B‐cell receptor signalling in B‐cell malignancies
Jerkeman, M., Hallek, M. J., Dreyling, M. H., Thiéblemont, C., Kimby, E. K., & Staudt, L. M. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12600 · Cited by 44
Self-citationYazbeck, V. Y., Shafer, D. A., Perkins, E. B., Coppola, D., Sokol, L., Richards, K. L., Shea, T. C., Ruan, J., Parekh, S. S., STRAIR, R. K., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.023 · Cited by 43
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
Pillinger, G., Abdul-Aziz, A. M., Zaitseva, L., Lawes, M. J., MacEwan, D. J., Bowles, K. M., & Rushworth, S. A. (2015) · Scientific Reports · doi:10.1038/srep12949 · Cited by 43
Lymphoma Immunotherapy: Current Status
Zappasodi, R., de Braud, F., & Nicola, M. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00448 · Cited by 42
Mantle Cell Lymphoma: Biology, Clinical Presentation, and Therapeutic Approaches
Dreyling, M. H. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.191 · Cited by 43
Self-citationIn Search of Magic Bullets: The Golden Age of Immunotherapeutics
O’Shea, J. J., Kanno, Y., & Chan, A. C. (2014) · Cell · doi:10.1016/j.cell.2014.03.010 · Cited by 44
Hess, G., Keller, U. B., Scholz, C. W., Witzens‐Harig, M., Atta, J. A., Buske, C., Kirschey, S., Ruckes, C., Medler, C., van Oordt, C. W. M. D. H., et al. (2015) · Leukemia · doi:10.1038/leu.2015.60 · Cited by 42
Self-citationCurrent Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Aw, A., & Brown, J. R. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0468-4 · Cited by 43
Salles, G. A., Gopal, A. K., Minnema, M. C., Wakamiya, K., Feng, H., Schecter, J. M., & Wang, M. L. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.013 · Cited by 42
Self-citationZhang, Q., Wang, H. Y., Liu, X., Nuñez-Cruz, S., Jillab, M., Melnikov, O., Nath, K., Glickson, J. D., & Wasik, M. A. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801327 · Cited by 42
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
Lew, T. E., Minson, A. G., Dickinson, M. J., Handunnetti, S. M., Blombery, P. A., Khot, A. S., Anderson, M. A., Ritchie, D., Tam, C. S. L., & Seymour, J. F. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00355-6 · Cited by 41
Zhuang, T., Wang, S., Yu, X., He, X., Guo, H., & Ou, C. (2024) · Biomarker Research · doi:10.1186/s40364-024-00639-0 · Cited by 41
Morrison, V. A., Jung, S., Johnson, J. L., LaCasce, A. S., Blum, K. A., Bartlett, N. L., Pitcher, B. N., & Cheson, B. D. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.938333 · Cited by 41
Self-citationTargeting the B-cell receptor signaling pathway in B lymphoid malignancies
Buchner, M., & Müschen, M. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000048 · Cited by 42
Chai, K. L., Rowan, G. D., Seymour, J. F., Burbury, K., Carney, D. A., & Tam, C. S. L. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1315115 · Cited by 41
Liu, D., Zhao, J., Song, Y., Luo, X., & Yang, T. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0703-z · Cited by 41
Inhibition of effector B cells by ibrutinib in systemic sclerosis
Einhaus, J. F., Pecher, A., Asteriti, E., Schmid, H., Secker, K.-A., Duerr‐Stoerzer, S., Keppeler, H., Klein, R., Schneidawind, C., Henes, J., et al. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02153-8 · Cited by 42
Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma
Wang, L., Mo, S., Li, X., He, Y., & Yang, H. J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0073 · Cited by 42
Wang, T., Kreuziger, L. B., Leader, A., Spectre, G., Lim, M. Y., Gahagan, A., Gangaraju, R., Sanfilippo, K. M., Mallick, R., Zwicker, J. I., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15367 · Cited by 41
BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma
Wiestner, A. U. (2014) · Hematology · doi:10.1182/asheducation-2014.1.125 · Cited by 41
Klánová, M., Lorková, L., Vít, O., Maswabi, B. C. L., Molinský, J., Pospíšilová, J., Vočková, P., Mavis, C. K., Latečková, L., Kulvait, V., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-159 · Cited by 40
Denzinger, V., Busygina, K., Jamasbi, J., Pekrul, I., Spannagl, M., Weber, C., Lorenz, R. L., & Siess, W. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1677744 · Cited by 40
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Lucas, F. M., & Woyach, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00635-7 · Cited by 40
Mu, S., Tang, Z., Novotny, W. F., Tawashi, M., Li, T.-K., Ou, Y. C., & Sahasranaman, S. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04015-w · Cited by 41
Small-molecule drug repurposing to target DNA damage repair and response pathways
Brinkman, J. A., Liu, Y., & Kron, S. J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.013 · Cited by 41
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function
Zheng, T. J., Lofurno, E. R., Melrose, A. R., Lakshmanan, H. H. S., Pang, J., Phillips, K. G., Fallon, M. E., Kohs, T. C. L., Ngo, A. T. P., Shatzel, J. J., et al. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00296.2020 · Cited by 42
Current and emerging therapies for primary central nervous system lymphoma
Yuan, Y., Ding, T., Wang, S., Chen, H., Mao, Y. Q., & Chen, T. (2021) · Biomarker Research · doi:10.1186/s40364-021-00282-z · Cited by 42
Myeloid Cells as Targets for Therapy in Solid Tumors
Cotechini, T., Medler, T. R., & Coussens, L. M. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000132 · Cited by 40
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Maharaj, K. K., Uriepero, A., Sahakian, E., & Pinilla-Ibarz, J. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943354 · Cited by 41
de Vries, R., Huang, M. Q., Bode, N., Jejurkar, P., de Jong, J., Sukbuntherng, J., Sips, L., Weng, N., Timmerman, P., & Verhaeghe, T. (2015) · Bioanalysis · doi:10.4155/bio.15.159 · Cited by 39
Breakthrough therapies in B-cell non-Hodgkin lymphoma
Cheah, C. Y., Fowler, N. H., & Wang, M. L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw029 · Cited by 39
Self-citationGene mutations and actionable genetic lesions in mantle cell lymphoma
Ahmed, M., Zhang, L. Y., Nomie, K. J., Lam, L. T., & Wang, M. L. (2016) · Oncotarget · doi:10.18632/oncotarget.10716 · Cited by 39
Self-citationMoyo, T. K., Wilson, C., Moore, D. J., & Eischen, C. M. (2017) · Oncogene · doi:10.1038/onc.2017.95 · Cited by 40
Schubert, M., Schmitt, A., Sellner, L., Neuber, B., Kunz, J. B., Wuchter, P., Kunz, A. B., Gern, U., Michels, B., Hofmann, S., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026644 · Cited by 40
Cortelazzo, S., Ponzoni, M., Ferreri, A. J. M., & Dreyling, M. H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103038 · Cited by 39
Self-citationThe potential of pirtobrutinib in multiple B-cell malignancies
Jensen, J. L., Mato, A. R., Peña, C., Roeker, L. E., & Coombs, C. C. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221101697 · Cited by 40
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Dong, R., Yan, Y., Zeng, X., Lin, N., & Tan, B. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s377697 · Cited by 39
Munshi, P. N., Hamadani, M., Kumar, A., Dreger, P., Friedberg, J. W., Dreyling, M. H., Kahl, B. S., Jerkeman, M., Kharfan‐Dabaja, M. A., Locke, F. L., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01288-9 · Cited by 38
Self-citationTargeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas
Etrych, T., Braunová, A., Zogala, D., Lambert, L., Renešová, N., & Klener, P. (2022) · Cancers · doi:10.3390/cancers14030626 · Cited by 38
Stanchina, M., Montoya, S., Danilov, A. V., Castillo, J. J., Alencar, A. J., Chavez, J. C., Cheah, C. Y., CHIATTONE, C. S., Wang, Y., Thompson, M. C., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00956-1 · Cited by 40
Sonbol, M. B., Maurer, M. J., Stenson, M. J., Allmer, C., LaPlant, B. R., Weiner, G. J., Macon, W. R., Cerhan, J. R., Witzig, T. E., & Gupta, M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23838 · Cited by 37
Blinatumomab for the treatment of B-cell lymphoma
Oak, E., & Bartlett, N. L. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1021415 · Cited by 37
Management of Ibrutinib Toxicities: a Practical Guide
Lasica, M., & Tam, C. S. L. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00576-3 · Cited by 38
Mehta, L., Naved, T., Grover, P., Bhardwaj, M., & Mukherjee, D. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113768 · Cited by 37
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
Jiang, C., Liu, Y., Lian, J., Huang, S., Jordan, A. A., Cai, Q., Lin, R., Yan, F., McIntosh, J. M., Li, Y., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165694 · Cited by 37
Self-citationSharman, J. P., & Paolo, J. A. D. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716636542 · Cited by 38
Czuczman, N. M., Barth, M. J., Gu, J. J., Neppalli, V. T., Mavis, C. K., Frys, S., Hu, Q., Liu, S., Klener, P., Vočková, P., et al. (2015) · Blood · doi:10.1182/blood-2015-04-640920 · Cited by 37
Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline
Eyre, T. A., Bishton, M. J., McCulloch, R., O'Reilly, M. A., Sanderson, R., Menon, G., Iyengar, S., Lewis, D. J., Lambert, J., Linton, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19131 · Cited by 36
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
Parrondo, R. D., Iqbal, M., von Roemeling, R., Roemeling, C. A. V., & Tun, H. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1239082 · Cited by 36
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
Wu, H., Hu, C., Wang, A., Weisberg, E., Wang, W., Chen, C., Zhao, Z., Yu, K., Liu, J., Wu, J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.175 · Cited by 37
Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism
Menzfeld, C., John, M., van Rossum, D., Regen, T., Scheffel, J., Jáňová, H., Götz, A. A., Ribes, S., Nau, R., Borisch, A., et al. (2015) · Glia · doi:10.1002/glia.22803 · Cited by 36
BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future
Spaargaren, M., de Rooij, M. F. M., Kater, A. P., & Eldering, E. (2014) · Oncogene · doi:10.1038/onc.2014.181 · Cited by 37
Bortezomib for the treatment of non-Hodgkin’s lymphoma
Bose, P., Batalo, M., Holkova, B., & Grant, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965142 · Cited by 38
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma
Rule, S. A., Cook, G., Russell, N. H., Hunter, A., Robinson, S. P., Morley, N. J., Sureda, A. M., Patrick, P., Clifton‐Hadley, L., Adedayo, T., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15723 · Cited by 36
Self-citationCalabretta, E., & Carlo‐Stella, C. (2020) · Cells · doi:10.3390/cells9040802 · Cited by 36
Charalambous, A., Schwarzbich, M., & Witzens‐Harig, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_7 · Cited by 36
Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
Kelly, K. R., Mejia, A. V., Suhasini, A. N., Lin, A., Kuhn, J. G., Karnad, A. B., Weitman, S. D., & Aguiar, R. C. T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1207 · Cited by 37
Middle, S., Coupland, S. E., Taktak, A. F. G., Kidgell, V., Slupsky, J. R., Pettitt, A. R., & Till, K. J. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0004-3 · Cited by 35
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
Dreyling, M. H., Ferrero, S., & on behalf of European Mantle Cell Lymphoma Network (2016) · Haematologica · doi:10.3324/haematol.2014.119115 · Cited by 36
Self-citationIbrutinib in Refractory Classic Hodgkin's Lymphoma
Hamadani, M., Balasubramanian, S., & Hari, P. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505857 · Cited by 35
Onea, A. S., & Jazirehi, A. R. (2016) · PubMed Central · Cited by 35
Lee, S., Luo, W., Shah, T., Yin, C., O'Connell, T. J., Chung, T., Perkins, S. L., Miles, R. R., Ayello, J. S., Morris, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15711 · Cited by 35
Mogamulizumab for the treatment of T-cell lymphoma
Makita, S., & Tobinai, K. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347634 · Cited by 39
Eades, C. P., & Armstrong-James, D. P. H. (2018) · Medical Mycology · doi:10.1093/mmy/myy136 · Cited by 35
Yang, Z., Du, Y., Lei, L., Xia, X., Wang, X., Tong, F., Li, Y., & Gao, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122436 · Cited by 38
Ibrutinib in B lymphoid malignancies
Smith, M. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1067302 · Cited by 34
Mantle cell lymphoma: state of the art.
Skarbnik, A. P. Z., & Goy, A. H. (2015) · PubMed · Cited by 34
Self-citationDiscovery of novel pyrazole derivatives as potential anticancer agents in MCL
Ran, F., Liu, Y., Zhang, D., Liu, M., & Zhao, G. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.005 · Cited by 34
Eskelund, C. W., Dimopoulos, K., Kolstad, A., Glimelius, I. C., Räty, R., Gjerdrum, L. M. R., Sonnevi, K., Josefsson, P. L., Nilsson‐Ehle, H., Bentzen, H., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000510 · Cited by 34
A patent review of MALT1 inhibitors (2013-present)
Hamp, I., O’Neill, T. J., Plettenburg, O., & Krappmann, D. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1951703 · Cited by 35
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Christensen, B. W., Zaha, V. G., & Awan, F. T. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2067526 · Cited by 35
Vaughn, J. E., Sorror, M. L., Storer, B. E., Chauncey, T. R., Pulsipher, M. A., Maziarz, R. T., Maris, M. B., Hari, P., Laport, G. G., Franke, G., et al. (2015) · Cancer · doi:10.1002/cncr.29498 · Cited by 34
Risk factors for etiology and prognosis of mantle cell lymphoma
Wang, Y., & Ma, S. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.889561 · Cited by 33
Tessoulin, B., Céballos, P., Chevallier, P., Blaise, D., Tournilhac, O., Gauthier, J., Maillard, N., Tabrizi, R., Choquet, S., Carras, S., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.102 · Cited by 33
He, Y., Li, J., Ding, N., Wang, X., Deng, L., Xie, Y., Ying, Z., Liu, W., Ping, L., Zhang, C., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1076-4 · Cited by 34
Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
Klener, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184417 · Cited by 33
CD19-directed CAR T-cell therapy in B-cell NHL
Kersten, M. J., Spanjaart, A. M., & Thiéblemont, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000668 · Cited by 33
Zhang, J., Lü, X., Li, J., & Miao, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00357-5 · Cited by 33
Appleby, N., Eyre, T. A., Cabes, M., Jackson, A. E., Boucher, R. H., Yates, F., Fox, S., Rawstron, A. C., Hillmen, P., & Schuh, A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5717-y · Cited by 33
Wang, S., Mondal, S., Zhao, C., Berishaj, M., Ghanakota, P., Batlevi, C. L., Doǧan, A., Seshan, V., Abel, R., Green, M. R., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127566 · Cited by 33
Tobinai, K., Ogura, M., Ishizawa, K., Suzuki, T., Munakata, W., Uchida, T., Aoki, T., Morishita, T., Ushijima, Y., & Takahara, S. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1900-3 · Cited by 33
Tucker, D. L., Naylor, G., Kruger, A. R., Hamilton, M. S., Follows, G., & Rule, S. A. (2016) · British Journal of Haematology · doi:10.1111/bjh.14122 · Cited by 32
Self-citationATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma
Ahmed, M., Li, L., Pinnix, C. C., Dabaja, B. S., Nomie, K. J., Lam, L. T., & Wang, M. L. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.008 · Cited by 32
Self-citationCharacterization of Covalent-Reversible EGFR Inhibitors
Smith, S. P., Keul, M., Engel, J., Basu, D., Eppmann, S., & Rauh, D. (2017) · ACS Omega · doi:10.1021/acsomega.7b00157 · Cited by 33
Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives
Seiler, T., & Dreyling, M. H. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1349097 · Cited by 32
Self-citationFunctional Characterization of 22 CYP 3A4 Protein Variants to Metabolize IbrutinibIn Vitro
Xu, R.-A., Wen, J. M., Tang, P.-F., Wang, C., Xie, S., Zhang, B., Zhou, Q., Cai, J., & Hu, G. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12934 · Cited by 32
Zhang, Z., Zhang, D., Liu, Y., Yang, D., Ran, F., Wang, M. L., & Zhao, G. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201700369 · Cited by 33
Self-citationAlsadhan, A., Cheung, J. P., Gulrajani, M., Gaglione, E. M., Nierman, P., Hamdy, A., Izumi, R. E., Бибикова, Е., Patel, P. S., Sun, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3505 · Cited by 32
Hepatitis B Virus Reactivation Potentiated by Biologics
Ogawa, E., Wei, M. T., & Nguyen, M. H. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.009 · Cited by 32
Cardiovascular Complications in Hematopoietic Stem Cell Transplanted Patients
Zhao, Y. H., He, R., Oerther, S., Zhou, W., Vosough, M., & Hassan, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111797 · Cited by 32
Modeling the Clinical Phenotype of BTK Inhibition in the Mature Murine Immune System
Benson, M. J., Rodriguez, V., von Schack, D., Keegan, S., Cook, T. A., Edmonds, J., Benoit, S., Seth, N. P., Du, S., Messing, D., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302570 · Cited by 33
Engel, J., Smith, S. P., Lategahn, J., Tumbrink, H. L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00515 · Cited by 32
Heterologous pathway assembly reveals molecular steps of fungal terreic acid biosynthesis
Kong, C., Huang, H., Xue, Y., Liu, Y., Peng, Q., Liu, Q., Xu, Q., Zhu, Q., Yin, Y., Zhou, X., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20514-x · Cited by 32
Acalabrutinib for mantle cell lymphoma
Witzig, T. E., & Inwards, D. J. (2019) · Blood · doi:10.1182/blood.2019852368 · Cited by 32
Modulation of immune checkpoint molecule expression in mantle cell lymphoma
Harrington, B. K., Wheeler, E., Hornbuckle, K., Shana’ah, A. Y., Youssef, Y., Smith, L., Hassan II, Q., Klamer, B., Zhang, X., Long, M., et al. (2019) · Leukemia & Lymphoma · doi:10.1080/10428194.2019.1569231 · Cited by 31
Araujo‐Ayala, F., Dobaño‐López, C., Valero, J. G., Nadeu, F., Gava, F., Faria, C., Norlund, M., Morin, R., Bernes-Lasserre, P., Serrat, N., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01885-1 · Cited by 31
Deng, L., Zhou, K., Liu, L., Zhang, M., Li, Z., Ji, C., Xu, W., Liu, T., Xu, B., Wang, X., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009168 · Cited by 31
Dreyling, M. H., Ferrero, S., Vogt, N., & Klapper, W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0836 · Cited by 31
Self-citationIbrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience
Castillo, J. J., Palomba, M. L., Advani, R. H., & Treon, S. P. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716654102 · Cited by 32
Self-citation
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
